A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 10, 2014, Pages 1126-1135

  Levesque, B G ^a,b   Greenberg, G R ^c   Zou, G ^a,d   Sandborn, W J ^a,b   Singh, S ^e   Hauenstein, S ^e   Ohrmund, L ^e   Wong, C J ^a   Stitt, L W ^a,d   Shackelton, L M ^a   King, D ^a   Lockton, S ^e   Ducharme, J ^f   Feagan, B G ^a,d  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e Prometheus Laboratories Inc   (United States)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HEMATOCRIT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RELAPSE; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; COHORT STUDIES; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84899129423     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12733     Document Type: Article

References (21)

1. Targan SR, Hanauer SB, van Deventer SJ, et al,. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
3. Colombel JF, Sandborn WJ, Reinisch W, et al,. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
4. Ordas I, Mould DR, Feagan BG, Sandborn WJ,. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012; 91: 635-46.
5. Baert F, Noman M, Vermeire S, et al,. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
6. Maser EA, Villela R, Silverberg MS, Greenberg GR,. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-54.
7. Seow CH, Newman A, Irwin SP, Stenhart AH, Silverberg MS, Greenberg GR,. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
8. Best WR, Becktel JM, Singleton JW, Kern F Jr,. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
9. Sandborn WJ, Schreiber S, Feagan BG, et al,. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011; 9: 670-8.e3.
10. Wang SL, Ohrmund L, Hauenstein S, et al,. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 2012; 382: 177-88.
11. Vande Casteele N, Gils A, Singh S, et al,. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108: 962-71.
12. Hanley JA, McNeil BJ,. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
13. Youden WJ,. Index for rating diagnostic tests. Cancer 1950; 3: 32-5.
14. Nanda KS, Cheifetz AS, Moss AC,. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013; 108: 40-7.
15. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA., Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011; 46: 310-8.
16. Cornillie F, Hanauer S, Diamond R, et al,. Early serum infliximab trough level, clinical disease activity and CRP as markers of sustained benefit of infliximab treatment in Crohn's disease: a post-hoc analysis of the ACCENT 1 trial. Am J Gastroenterol 2011; 106: S462.
17. Lahiff C, Safaie P, Awais A, et al,. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2013; 37: 786-94.
18. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinmeister AR, Sandborn WJ., Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 707-12.
19. Pariente B, Pineton de Chambrun G, et al,. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 1199-206.
20. Ben-Horin S, Yavzori M, Katz L, et al,. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41-8.
21. Imaeda H, Andoh A, Fujiyama Y,. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol 2012; 47: 136-43.